Popular Articles

Heart Failure Patients With Cognitive Impairment Have Higher Mortality Risk
"There are data in the literature suggesting an increased mortality in patients with chronic heart failure who are additionally suffering from cognitive decline", said Dr. Clotilde Balucani (Perugia, Italy) at the current meeting of the European Neurological Society (ENS). This major meeting in European neurology is gathering more than 2,900 experts from all over the world in Milan. Dr. Balucani and her colleagues are presenting a study funded by a research grant of the ENS.
pharmacy online
Food For Thought: Report Published Into The UK's Health
Medical scientists from Southampton have contributed to a major new report published today, setting out plans to enhance the nation"s health by improving diet, increasing physical activity and cutting harmful drinking.
News of the day
Study Of Pulmonary Hypertension Treatment In Sickle Cell Patients Halted By NHLBI
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns. In an interim review of safety data from 33 participants who completed 16 weeks of treatment, researchers found that, compared to participants on placebo (dummy pill), participants taking sildenafil (Revatio) were significantly more likely to have serious medical problems. The most common problem was episodes of severe pain called sickle cell crises, which resulted in hospitalization. No deaths have been associated with the drug in the clinical trial.
Diagnostics

Faster, Cheaper Genome Sequencing Featured At The 15-Minute Genome 2009 Industrial Physics Forum

In the race for faster, cheaper ways to read human genomes, Pacific Biosciences is hoping to set a new benchmark with technology that watches DNA being copied in real time. The device is being developed to sequence DNA at speeds 20,000 times faster than second-generation sequencers currently on the market and will ultimately have a price tag of $100 per genome. Chief Technology Officer Stephen Turner of Pacific Biosciences discussed Single Molecule Real-Time (SMRT) sequencing, due to be released commercially in 2010, at the 2009 Industrial Physics Forum, a component of the 51st Annual Meeting of American Association of Physicists in Medicine, which takes place from July 26 - 30 in Anaheim, California A decade ago, it took Celera Genomics and the Human Genome Project years to sequence complete human genomes. In 2008, James Watson"s entire genetic code was read by a new generation of technology in months. SMRT sequencing aims to eventually accomplish the same feat in minutes. The method used in the Human Genome Project, Sanger sequencing, taps into the cell"s natural machinery for replicating DNA. The enzyme DNA polymerase is used to copy strands of DNA, creating billions of fragments of varying length. Each fragment -- a chain of building blocks called nucleotides -- ends with a tiny fluorescent molecule that identifies only the last nucleotide in the chain. By lining these fragments up according to length, their glowing tips can be read off like letters on a page. Instead of inspecting DNA copies after polymerase has done its work, SMRT sequencing watches the enzyme in real time as it races along and copies an individual strand stuck to the bottom of a tiny well. Every nucleotide used to make the copy is attached to its own fluorescent molecule that lights up when the nucleotide is incorporated. This light is spotted by a detector that identifies the color and the nucleotide -- A, C, G, or T. By repeating this process simultaneously in many wells, the technology hopes to bring about a substantial boost in sequencing speed. "When we reach a million separate molecules that we"re able to sequence at once ò€¦ we"ll be able to sequence the entire human genome in less than 15 minutes," said Turner. The speed of the reaction is currently limited by the ability of the detector to keep up with the polymerase. The first commercial instrument will operate at three to five bases per second, and Turner reports that lab tests have achieved 10 bases per second. The polymerase has the potential to go much faster, up to hundreds of bases per second. "To push past 50 bases per second, we will need brighter fluorescent reporters or more sensitive detection," says Turner. The device also has the potential to reduce the number of errors made in DNA sequencing. Current technologies achieve an accuracy of 99.9999 percent (three thousand errors in a genome of three billion base pairs). "For cancer, you need to be able to spot a single mutation in the genome," said Turner. Because the errors made by SMRT sequencing are random -- not systematically occurring at the same spot -- they are more likely to disappear as the procedure is repeated. The talk, "Single Molecule Real-Time DNA Sequencers," was given on Monday, July 27. Devin Powell American Institute of Physics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):